ERD-308

• UNSPSC Description:

  ERD-308 is a highly potent von Hippel-Lindau-based PROTAC degrader of estrogen receptor (ER) for ER positive breast cancer treatment. ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively)[1].

• Target Antigen:

  Estrogen Receptor/ERR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Vitamin D Related/Nuclear Receptor

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/erd-308.html

• Purity:

  99.17

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(C2=CC=C(O)C=C2)SC3=CC(O)=CC=C13)C4=CC=C(OCCN(CCCCCOCC(N[C@@H](C(C)(C)C)C(N5[C@H](C(N[C@@H](C)C6=CC=C(C7=C(C)N=CS7)C=C6)=O)C[C@@H](O)C5)=O)=O)CC)C=C4

• Molecular Weight:

  1004.26

• References & Citations:

  [1]Hu J, et al. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J Med Chem. 2019 Feb 14;62(3):1420-1442.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  2320561-35-9